Immutep Limited (IMMP)
Pre-market:
| Previous close | 2.9200 |
| Open | 3.0000 |
| Bid | 2.9300 x 100 |
| Ask | 2.9800 x 200 |
| Day's range | 2.9400 - 3.0791 |
| 52-week range | 1.5800 - 3.0900 |
| Volume | |
| Avg. volume | 222,414 |
| Market cap | 361.389M |
| Beta (5Y monthly) | 1.79 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
Immutep Presents Data from Safety Lead-in Phase of AIPAC-003 at ESMO Breast 2024
Media Release Confirmed complete response in a patient with metastatic breast cancer refractory to several lines of therapy achieved during combination treatment with 90mg efti and paclitaxelOngoing complete response has been maintained since the patient started treatment with efti monotherapyEfti + paclitaxel combination continues to be well tolerated with a favourable safety profileFirst-ever 90mg dosing leads to higher maximum concentration of efti, as well as pharmacologically active level u
- GlobeNewswire
Positive Initial Clinical Data Reported from Immutep’s Efti Combined with Radiotherapy and Checkpoint Inhibitor from Phase II Trial in Soft Tissue Sarcoma
Media Release Novel triple combination of efti with radiotherapy and anti-PD-1 therapy is well tolerated and has led to encouraging initial efficacy data in EFTISARC-NEO Phase II trialFour of six patients treated have very good, near-complete pathologic responses (primary endpoint of study) that are rarely observed with standard therapiesSoft tissue sarcoma is a hard-to-treat orphan disease with poor prognosis & high unmet medical needAdditional data from EFTISARC-NEO planned for a medical confe
- GlobeNewswire
Immutep Quarterly Activities Report Q3 FY24
Media Release First clinical data from the safety lead-in of AIPAC-003 in metastatic breast cancer shows 90mg dosing of efti safe and well tolerated: 50% overall response rate, including one patient reporting a complete response (complete disappearance of all lesions), and a 100% disease control rateSubsequent to quarter end announced a positive preliminary response rate of 26.9% in first line metastatic head and neck squamous cell carcinoma patients with negative PD-L1 expressionPreclinical stu
